C012 | NOVEL ANALYSIS OF RESULTS FROM THE PIVOTAL EPCORE NHL-1 STUDY: OUTCOMES IN PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA AND COMPLETE RESPONSE AT 2-YEARS WITH EPCORITAMAB MONOTHERAPY

Background: Depth and duration of CR correlate with long-term outcomes in LBCL. Epcor is a subcutaneous CD3xCD20 bispecific antibody approved for the treatment (tx) of pts with DLBCL or high-grade BCL after ≥2 lines of tx (LOT). In the 3-y follow-up (FU) from NHL-1 (NCT03625037), epcor led to durab...

Full beskrivning

Bibliografiska uppgifter

Huvudupphov:	P.L. Zinzani, Y. H. Karimi, J.M. Vose, M. Roost Clausen, D. Cunningham, U. Farooq, T. Feldman, H. Ghesquieres, W. Jurczak, K.M. Linton, T. Phillips, W.S. Kim, P. Jafarinasabian, M. Geybels, D. Soong, B. D. Månsson, C. W. Eskelund, M. Atiya, M. Hutchings, C. Thieblemont, C.Y. Cheah
Materialtyp:	Artigo
Språk:	Inglês
Utgiven:	Ferrata Storti Foundation 2025-09-01
Serie:	Haematologica
Länkar:	https://haematologica.org/article/view/12876
Taggar:	Lägg till en tagg Inga taggar, Lägg till första taggen!